4D Molecular Therapeutics, Inc. Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount
4D Molecular Therapeutics, Inc. (FDMT) had Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount of $0 as of 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount · last filed 2022-05-12
- 2022-03-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-12-31: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-09-30: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
- 2021-06-30: Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount $0.00.
| Period end | Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
| 2021-12-31 | $0.00 10-Q · filed 2022-05-12 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-10 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-28 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |